Spectrum of Presentation of Benign Breast Diseases and Role of Danazol in its Management in a Tertiary Care Hospital of South Odisha, India
Author(s): Niranjan Sahoo, Sanjeeb Kumar Pradhan, Sanjit Kumar Nayak, Swapna Mahapatra* and Manjul Kanta Pradhan
Abstract
Objective: To assess different spectrum of presentation of Benign breast diseases (BBD) and role of the drug Danazol in management. Materials and methods: This was a prospective study. 92 patients of benign breast disease (BBD) were taken as study population. All the patients with complains of pain and lump in the breast with diagnosed case of benign breast disease in OPD or admitted in Department of General Surgery, M.K.C.G. Medical College & Hospital, Berhampur, were taken into consideration for the study period from July 2017 to June 2019. Results: In this study it is found that, most common benign breast disease found to be fibroadenoma 52%, followed by fibroadenosis 40%, phylodestumour 5% and duct ectasia 3%. Incidence of benign breast disease was more in adolescent and young adult female around 70%.Danazol in a dose of 100mg twice daily orally and short course of 3 months could result in elimination of nodularity and pain in 62.5% in fibroadenosis, decrease symptoms of fibroadenosis in 30% cases and no response in 7.5%. Side effects of Danazol were also found but it was only 5% as menstrual irregularities and 2.5% had weight gain and rest 92.5% had no side effect. Conclusion: Endocrine manipulation in benign beast disease by using Danazol in low dose and short period result in reduction of tumour size with minimal side effect significantly.